SCH-221510

SCH-221510
Names
	IUPAC name (1S,5R)-8-[Bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol
Identifiers
CAS Number	322473-89-2;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL513136;
ChemSpider	35143261;
IUPHAR/BPS	8868;
PubChem CID	24879901;
CompTox Dashboard (EPA)	DTXSID10432414;
	InChI InChI=1S/C28H31NO/c1-20-10-6-8-14-25(20)27(26-15-9-7-11-21(26)2)29-23-16-17-24(29)19-28(30,18-23)22-12-4-3-5-13-22/h3-15,23-24,27,30H,16-19H2,1-2H3/t23-,24+,28? Key: LOSJNRBXNQTUNT-XUEDKKMFSA-N;
	SMILES CC1=CC=CC=C1C(C2=CC=CC=C2C)N3[C@@H]4CC[C@H]3CC(C4)(C5=CC=CC=C5)O;
Properties
Chemical formula	C28H31NO
Molar mass	397.562 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

SCH-221510 is an experimental opioid drug. It has potential as an analgesic and as a treatment to addiction of certain drugs.

Mechanism of action

Most opioid analgesics act through delta, mu, and kappa opioid receptors; however, SCH-221510 is instead an agonist at the nociceptin receptor.^[1]

Analgesic effects

Classical opioid analgesics (such as morphine) usually have effects such as constipation, hypoventilation and addiction.^[2] However, by acting through a different receptor, SCH-221510 seems to be lacking the undesirable effects of morphine at equianalgesic doses.^[1] This suggests that SCH-221510 could be a better opioid than the currently available opioid pain medications, by having less side effects.

Treatment of drug addiction

SCH-221510 might be an option in the treatment of certain drug addictions: it is able to decrease ethanol self-administration^[3] and was able to decrease self-administration of remifentanil, a fentanyl analogue, in a study,^[4]

References

^ ^a ^b Lin, Ann P.; Ko, Mei-Chuan (2012-10-24). "The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse Liability". ACS Chemical Neuroscience. 4 (2): 214–224. doi:10.1021/cn300124f. ISSN 1948-7193. PMC 3582300. PMID 23421672.
^ Nakatani, Toshihiko (April 2017). "[Opioid Therapy and Management of Side Effects Associated with Opioids]". Gan to Kagaku Ryoho. Cancer & Chemotherapy. 44 (4): 294–297. ISSN 0385-0684. PMID 28428507.
^ Flynn, Shawn M.; Epperly, Phillip M.; Davenport, April T.; Cami-Kobeci, Gerta; Husbands, Stephen M.; Ko, Mei-Chuan; Czoty, Paul W. (July 2019) [Published online: 10 April 2019]. "Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys". Neuropsychopharmacology. 44 (8): 1476–1484. doi:10.1038/s41386-019-0390-z. ISSN 1740-634X. PMC 6784996. PMID 30970376.
^ Sukhtankar, Devki D.; Lagorio, Carla H.; Ko, Mei-Chuan (2014-12-15). "Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats". European Journal of Pharmacology. 745: 182–189. doi:10.1016/j.ejphar.2014.10.029. ISSN 1879-0712. PMC 4259829. PMID 25446568.

[:0-1] Lin, Ann P.; Ko, Mei-Chuan (2012-10-24). "The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse Liability". ACS Chemical Neuroscience. 4 (2): 214–224. doi:10.1021/cn300124f. ISSN 1948-7193. PMC 3582300. PMID 23421672.

[2] Nakatani, Toshihiko (April 2017). "[Opioid Therapy and Management of Side Effects Associated with Opioids]". Gan to Kagaku Ryoho. Cancer & Chemotherapy. 44 (4): 294–297. ISSN 0385-0684. PMID 28428507.

[3] Flynn, Shawn M.; Epperly, Phillip M.; Davenport, April T.; Cami-Kobeci, Gerta; Husbands, Stephen M.; Ko, Mei-Chuan; Czoty, Paul W. (July 2019) [Published online: 10 April 2019]. "Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys". Neuropsychopharmacology. 44 (8): 1476–1484. doi:10.1038/s41386-019-0390-z. ISSN 1740-634X. PMC 6784996. PMID 30970376.

[4] Sukhtankar, Devki D.; Lagorio, Carla H.; Ko, Mei-Chuan (2014-12-15). "Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats". European Journal of Pharmacology. 745: 182–189. doi:10.1016/j.ejphar.2014.10.029. ISSN 1879-0712. PMC 4259829. PMID 25446568.

[1]

[2]

[3]

[4]